

American dwarf palm tree, cabbage palm
Saw palmetto is a small, slow-growing palm native to southeastern United States. The fruits are a rich source of fatty acids and phytosterols and have been used to promote urination, reduce inflammation, and for treatment of prostatic conditions such as benign prostatic hyperplasia (BPH).
Saw palmetto has been studied in many controlled clinical trials. Whereas data from some studies indicate that it improves lower urinary tract symptoms in patients with benign prostatic hyperplasia (2) (3) (4) (5) (15) (17) (18) (26), conflicting data suggest no such effects (6) (14) (19) (28). A recent study showed that saw palmetto may benefit patients with chronic bacterial prostatitis when coadministered with Urtica dioica, curcumin and quercitin (16). Pretreatment with saw palmetto reduced intra- and postoperative complications in patients who underwent transurethral resection of the prostate and open prostatectomy (22). However, saw palmetto use was not associated with risk of prostate cancer (27).
Saw palmetto extract was found to inhibit growth of normal prostate cells and increase their sensitivity to radiation in vitro, but did not affect malignant prostate cancer cells (20). Patients should avoid use of saw palmetto supplements during radiotherapy for prostate cancer.
Studies with a liposterolic extract of saw palmetto berries showed that it reduced the uptake by tissue specimens of both testosterone and dihydrotestosterone (DHT) by more than 40% suggesting antiandrogenic activity (7). Further, the extract inhibited binding of DHT to its receptor (8) and blocked the conversion of testosterone to DHT by inhibiting the activity of 5-alpha-reductase (9). The berries also inhibit cyclooxygenase and 5-lipoxygenase pathways, thereby preventing the biosynthesis of inflammation-producing prostaglandins and leukotrienes (10).
Analysis of saw palmetto components including lauric acid, oleic acid, and beta-sitosterol in rats revealed wide distribution. Highest concentrations were found in abdominal fat, prostate, and skin, while lesser amounts were found in bladder and liver.
(13)
Bent S, et al. Saw Palmetto for Benign Prostatic Hyperplasia. N Engl J Med 2006; 354(6): 557- 566.Two hundred and twenty-five men (over the age of 49 years) with moderate-to-severe symptoms of benign prostatic hyperplasia (BPH) were randomized to receive saw palmetto extract (160 mg twice a day) or placebo for one year. There was no significant difference in the primary outcome measures — the American Urological Association Symptom Index (AUASI) scores or the maximal urinary flow rates between patients taking saw palmetto or placebo. Also, no significant differences were observed in prostate size, residual volume after voiding, quality of life, or serum PSA levels between the two groups.
These data contradict several earlier studies in which saw palmetto appeared to be a promising alternative for BPH. Researchers point to the methodologic flaws in those studies, including shorter duration of study, failure to use validated symptom scores, and ineffective blinding.
Bottom Line: Saw palmetto was shown in some studies to help relieve the symptoms of benign prostatic hypertrophy (BPH), but there is no proof that it can prevent or treat prostate cancer.
Studies in the laboratory and in animals show that saw palmetto works by countering the effects of androgens (the male sex hormones), such as testosterone and DHT. It is thought that saw palmetto does not reduce the levels of these hormones circulating in the blood, but causes body tissues (like the prostate) to take in lower levels of the hormones. Other studies have noted that saw palmetto reduces the conversion of testosterone to the DHT, its more potent form, by inhibiting the enzyme 5 alpha reductase. Saw palmetto berry extracts also reduce inflammation and edema in laboratory studies by inhibiting the formation of compounds that cause these reactions.
Saw palmetto extract was found to inhibit growth of normal prostate cells and increase their sensitivity to radiation in vitro, while not affecting prostate cancer cells. Patients should avoid use of saw palmetto supplements during radiotherapy for prostate cancer.
Benign prostatic hypertrophy (BPH)
Two hundred and twenty-five men (over the age of 49 years) with moderate-to-severe symptoms of benign prostatic hyperplasia (BPH) were given saw palmetto extract (160 mg twice a day) or placebo for one year. There was no significant difference in the American Urological Association Symptom Index (AUASI) scores or the maximal urinary flow rates between patients taking saw palmetto or placebo. Also, no significant differences were observed in prostate size, quality of life, or serum prostate specific antigen (PSA) levels between the two groups.